Emerging solutions for neovascular age-related macular degeneration
Therapeutic innovation in nAMD is transitioning from incremental refinements in intravitreal anti-VEGF delivery to strategies aimed at extending durability or targeting alternative contributory pathways. Long-term safety, efficacy, and durability will determine which of these candidates redefine standard care.
Authors
- Thomas J. Wubben (ORCID: https://orcid.org/0000-0002-5183-3817)
- Jovany J. Franco (ORCID: https://orcid.org/0000-0001-6206-6265)
Institutions
- University of Michigan (US)
Publication Details
- Journal
- Current Opinion in Ophthalmology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1097/icu.0000000000001199
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00